Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study | Zendy

A. Berdelou | Zendy; Valérie Boige | Zendy; Julia ArfiRouche | Zendy; David Malka | Zendy; Stéphane Éderhy | Zendy; Hassan Izzedine | Zendy; Sophie Leboulleux | Zendy; C. Chougnet | Zendy; Pascal Burtin | Zendy; Thierry de Baère | Zendy; Agnès Laplanche | Zendy; Dominique Elias | Zendy; Martin Schlumberger | Zendy; Jean–Yves Scoazec | Zendy; Michel Ducreux | Zendy; Éric Baudin | Zendy

Open Access

Not All Patients with a Pancreatic Neuroendocrine Tumour Will Benefit from All Approved or Recommended Therapeutic Options: A Real-Life Retrospective Study

Author(s) -

A. Berdelou,

Valérie Boige,

Julia ArfiRouche,

David Malka,

Stéphane Éderhy,

Hassan Izzedine,

Sophie Leboulleux,

C. Chougnet,

Pascal Burtin,

Thierry de Baère,

Agnès Laplanche,

Dominique Elias,

Martin Schlumberger,

Jean–Yves Scoazec,

Michel Ducreux,

Éric Baudin

Publication year - 2016

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000446988

Subject(s) - medicine , neutropenia , neuroendocrine tumors , sepsis , toxicity , clinical endpoint , retrospective cohort study , therapeutic effect , therapeutic approach , oncology , surgery , disease , clinical trial

At least nine therapeutic options are recommended or approved for pancreatic neuroendocrine tumour (pNET). The primary endpoint of this study was to determine the number of therapeutic lines given before death. Secondary endpoints were to determine toxic events as a function of number of therapeutic lines and of time.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research